.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,412,992

« Back to Dashboard

Claims for Patent: 4,412,992

Title: 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
Abstract:The present invention provides a pharmaceutical composition for treating ulcerative colitis containing at least one compound of the general formula: ##STR1## wherein X is an --SO.sub.2 -- or --CO-- group and R is either an unsubstituted or substituted non-heterocyclic aromatic ring system or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an unsubstituted or substituted amino group or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by unsubstituted or substituted amino groups or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier. Furthermore, the present invention provides a process for preparing the compounds of the above-given general formulae and also provides a method of treating ulcerative colitis.
Inventor(s): Chan; Rosalind P. K. (London, GB2)
Assignee: Biorex Laboratories Limited (GB2)
Application Number:06/281,504
Patent Claims: 1. 2-Hydroxy-5-phenylazobenzoic acid derivatives of the general formula: ##STR6## wherein X is an --SO.sub.2 -- or --CO-- group and R is either a phenyl or carboxymethylphenyl radical or is a radical of the formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an amino group, a monoalkyl- or dialkyl-amino group, the alkyl moieties of which contain up to 6 carbon atoms or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more of the hydrogen atoms in the alkylene radical can be replaced by amino groups, monoalkyl- or dialkyl-amino groups, the alkyl moieties of which contain up to 6 carbon atoms or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring, with the proviso that R--NH--X-- is other than a --CO--NH--CH.sub.2 --COOH radical; and the esters and non-toxic, pharmacologically acceptable salts thereof.

2. 5-(4-Phenylsulphamoylphenylazo)-salicylic acid and the sodium salt thereof.

3. Disodium salt of 5-(4-carboxymethylcarbamoylphenylazo)-salicylic acid.

4. 5-(Carboxyethylcarbamoyl-4-phenylazo)-salicylic acid and the disodium salt thereof.

5. 5-(Sulphoethylcarbamoyl-4-phenylazo)-salicylic acid.

6. 5-(4-Hydroxyethylcarbamoylphenylazo)-salicylic acid and the sodium salt thereof.

7. 5-(.alpha.-Methylcarboxymethylcarbamoyl-4-phenylazo)-salicylic acid.

8. 5-[(4-Carboxymethylphenyl)-sulphamoyl-4-phenylazo]-salicylic acid.

9. 5-(Carboxypentylcarbamoyl-4-phenylazo)-salicylic acid.

10. 5-(.alpha.-Dimethylaminocarboxypentylcarbamoyl-4-phenylazo)-salicylic acid and the disodium salt thereof.

11. 5-(Diethylaminoethylcarbamoyl-4-phenylazo)-salicylic acid.

12. A pharmaceutical composition for the treatment of ulcerative colitis in humans, containing an effective amount to treat ulcerative colitis, of at least one compound of the formula: ##STR7## wherein X is an --SO.sub.2 -- or --CO-- group and R is either phenyl or carboxymethylphenyl radical or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an amino group or a monoalkyl- or dialkyl-amino group, the alkyl moieties of which contain up to 6 carbon atoms or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by amino groups, monoalkyl- or dialkyl-amino groups, the alkyl moieties of which contain up to 6 carbon atoms or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier.

13. A method of treating ulcerative colitis in a human, wherein a compound of the formula given in claim 12, optionally in admixture with a solid or liquid pharmaceutical diluent or carrier, is administered orally to a human suffering from ulcerative colitis in a daily dosage of from 500 to 5000 mg.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc